https://www.dompe.com/content/dompefarmaceutici.htmlhttps://www.dompe.com/content/dompefarmaceutici/global.html2025-12-02https://www.dompe.com/2026-06-12https://www.dompe.com/about-us/2026-06-12https://www.dompe.com/about-us/who-we-are/2026-01-13https://www.dompe.com/about-us/who-we-are/history/2026-01-13https://www.dompe.com/about-us/who-we-are/management-team/2026-01-12https://www.dompe.com/about-us/who-we-are/management-team/leadership/sergio-dompe/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/leadership/nathalie-dompe/2025-12-02https://www.dompe.com/about-us/who-we-are/management-team/innovation/shannon-k--sullivan/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/innovation/marcello-allegretti/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/innovation/ahmed-enayetallah/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/business-and-operation/marc-kubasak/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/business-and-operation/davide-polimeni/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/business-and-operation/stefano-arena/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/business-and-operation/gianluca-rossetti/2026-02-06https://www.dompe.com/about-us/who-we-are/management-team/enabling-functions/giuseppe-andreano/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/enabling-functions/andrea-astolfi/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/enabling-functions/monica-fantino/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/enabling-functions/guido-romeo/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/enabling-functions/daniele-rizzo/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/enabling-functions/sheila-folayan/2025-12-03https://www.dompe.com/about-us/who-we-are/management-team/enabling-functions/marco-radice/2025-12-03https://www.dompe.com/about-us/who-we-are/environment-quality-and-safety/2026-06-12https://www.dompe.com/about-us/who-we-are/ethics-and-compliance/2026-06-08https://www.dompe.com/about-us/where-we-are/2026-06-12https://www.dompe.com/about-us/where-we-are/manufacturing-biotech/2026-06-12https://www.dompe.com/about-us/where-we-are/manufacturing-pharma/2026-06-12https://www.dompe.com/about-us/where-we-are/offices/2026-02-04https://www.dompe.com/science/2025-12-02https://www.dompe.com/science/nerve-growth-factor/2026-06-12https://www.dompe.com/science/pipeline/2026-06-12https://www.dompe.com/science/disease-focus/2025-12-02https://www.dompe.com/science/disease-focus/neurotrophic-keratitis/2026-06-12https://www.dompe.com/science/disease-focus/non-arteritic-anterior-ischemic-optic-neuropathy/2026-06-12https://www.dompe.com/science/disease-focus/atopic-keratoconjunctivitis/2026-06-12https://www.dompe.com/science/disease-focus/cerebral-palsy/2026-06-12https://www.dompe.com/science/disease-focus/persistent-corneal-epithelial-defect/2026-06-12https://www.dompe.com/science/exscalate/2026-06-12https://www.dompe.com/medicines/2025-12-02https://www.dompe.com/medicines/primary-and-specialty-care/2025-12-02https://www.dompe.com/medicines/primary-and-specialty-care/pain-and-inflammation/2026-06-12https://www.dompe.com/medicines/primary-and-specialty-care/cold-and-cough/2026-04-28https://www.dompe.com/medicines/primary-and-specialty-care/gastro/2026-04-28https://www.dompe.com/medicines/primary-and-specialty-care/cardiovascular/2026-06-12https://www.dompe.com/medicines/primary-and-specialty-care/eye-skin-and-oral-care/2026-04-28https://www.dompe.com/medicines/primary-and-specialty-care/prevention/2026-03-10https://www.dompe.com/medicines/ophthalmics/2026-03-10https://www.dompe.com/medicines/managed-access-programs/2026-06-12https://www.dompe.com/media/2025-12-02https://www.dompe.com/media/news/2025-12-10https://www.dompe.com/media/news/story/for-a-knowledge-economy-fondazione-dompe-strengthens-its-support-to-pavia-with-three-scholarships-dedicated-to-phd-students/2025-12-02https://www.dompe.com/media/news/story/fabbriche-aperte-dompe-welcomes-tomorrow-s-talent-for-a-journey-through-research-innovation-and-made-in-italy-excellence/2025-12-02https://www.dompe.com/media/news/story/dompe-primary-care-three-self-medication-products-in-the-top-ten/2025-12-02https://www.dompe.com/media/news/story/dompe-expands-l-aquila-facility-with-new-syrup-and-mouthwash-production-line/2025-12-02https://www.dompe.com/media/news/story/translational-research-on-neurotrophins-from-corneal-disease-to-the-central-nervous-system/2025-12-02https://www.dompe.com/media/news/story/why-early-detection-of-neurotrophic-keratitis-is-crucial/2025-12-02https://www.dompe.com/media/news/story/unleashing-innovation-dompe-s-journey-into-the-digital-age-of-pharma/2025-12-02https://www.dompe.com/media/news/story/rare-disease-day-2024/2025-12-02https://www.dompe.com/media/news/story/investing-in-training-i-ve-gained-valuable-insights-to-help-my-team-meet-key-timelines-for-clinical-trials/2025-12-02https://www.dompe.com/media/news/story/the-future-generation-of-life-sciences/2025-12-02https://www.dompe.com/media/news/story/tg1-il-capo-dello-stato-ha-incontrato-i-vincitori-del-premio-leonardo-che-seleziona-le-eccellenze-del-paese-in-diversi-settori/2025-12-02https://www.dompe.com/media/news/story/the-dompe-foundation-kicks-off-the-2023-2024-program-with-44-scholarship-in-us-and-italy/2025-12-02https://www.dompe.com/media/news/story/exscalate-meet-our-partners-pieter-stouten-exscalate-s-consultant-for-computational-technologies-in-pharma/2025-12-02https://www.dompe.com/media/news/story/exscalate-meet-our-partners-giulio-vistoli-full-professor-of-pharmaceutical-chemistry-at-the-department-of-pharmaceutical-sciences-university-of-milan/2025-12-02https://www.dompe.com/media/news/story/exscalate-meet-our-partners-gianluca-palermo-full-professor-of-computer-engineering-at-politecnico-di-milano/2025-12-02https://www.dompe.com/media/news/story/exscalate-meet-our-partners-torsten-schwede-vice-president-for-research-university-of-basel/2025-12-02https://www.dompe.com/media/news/story/discover-more-about-the-dompe-foundation-here-s-the-new-video/2025-12-02https://www.dompe.com/media/news/story/dompe-lights-up-the-researchers-night-with-sharper/2025-12-02https://www.dompe.com/media/news/story/the-authenticity-appreciated-by-horses-reveals-leadership-ability/2025-12-02https://www.dompe.com/media/news/story/discover-the-story-of-akash-from-assam-to-naples/2025-12-02https://www.dompe.com/media/news/story/teta-seminar-an-opportunity-for-personal-growth/2025-12-02https://www.dompe.com/media/news/story/stage-on-stage-from-the-voice-of-our-interns/2025-12-02https://www.dompe.com/media/news/story/mbti-a-leadership-that-thrives-in-diversity/2025-12-02https://www.dompe.com/media/news/story/equine-guided-learning-a-journey-of-self-discovery-to-empower-managers-with-leadership-skills/2025-12-02https://www.dompe.com/media/news/story/dompe-pharmaceuticals-environmental-commitment/2025-12-02https://www.dompe.com/media/news/story/a-colorful-celebration-of-diversity-inclusion-bimbi-in-dompe-day-unites-hearts-and-minds/2025-12-02https://www.dompe.com/media/news/story/we-embrace-discover-our-commitment-to-science-in-the-interest-of-patients/2025-12-02https://www.dompe.com/media/news/story/gary-pisano-the-future-of-the-business-of-bioscience/2025-12-02https://www.dompe.com/media/news/story/the-importance-of-rare-diseases-rarity-should-not-be-ignoredd/2025-12-02https://www.dompe.com/media/news/story/l-aquila-an-increasingly-green-and-biotech-production-hub/2025-12-02https://www.dompe.com/media/news/story/embracing-the-challenge-in-science-from-intuition-to-the-future-of-innovation/2025-12-02https://www.dompe.com/media/news/story/dompe-is-a-partner-of-the-first-monographic-exhibition-in-the-usa-dedicated-to-leonardo-da-vinci-s-codex-atlanticus/2025-12-02https://www.dompe.com/media/news/story/published-results-for-the-combined-treatment-of-nerve-growth-factor-and-transcranial-direct-current-stimulations-to-improve-outcome-in-children-with-the-vegetative-state-after-out-of-hospital-cardiac-arrest-study/2025-12-02https://www.dompe.com/media/news/story/exscalate4cov-is-now-a-book-on-high-performance-computing-for-covid-drug-discovery/2025-12-02https://www.dompe.com/media/news/story/rafael-cypriano-dutra-one-of-the-world-s-most-cited-scientists-is-in-dompe-s-labs/2025-12-02https://www.dompe.com/media/news/story/embracing-the-challenge-in-science-dompe-s-research-from-neurotrophins-to-ai-driven-drug-discovery/2025-12-02https://www.dompe.com/media/news/story/from-denmark-to-spain-and-italy-the-journey-of-a-researcher/2025-12-02https://www.dompe.com/media/news/story/the-dompe-of-tomorrow/2025-12-02https://www.dompe.com/media/news/story/international-day-for-the-elimination-of-violence-against-women-together-we-say-no/2025-12-02https://www.dompe.com/media/news/story/our-digital-transformation/2025-12-02https://www.dompe.com/media/news/story/integrated-technology-platform-for-the-identification-and-development-of-new-drugs-for-the-treatment-of-rare-diseases-or-diseases-with-a-high-unmet-need-for-treatment/2025-12-02https://www.dompe.com/media/news/story/supercomputers-at-the-service-of-drug-discovery-this-is-how-exscalate-was-born/2025-12-02https://www.dompe.com/media/news/story/digital-clinical-trials/2025-12-02https://www.dompe.com/media/news/story/digital-security/2025-12-02https://www.dompe.com/media/news/story/innovating-to-grow-from-rare-diseases-to-covid/2025-12-02https://www.dompe.com/media/news/story/exscalate-the-future-is-already-here/2025-12-02https://www.dompe.com/media/news/story/collaborate-to-innovate-follow-the-live-event/2025-12-02https://www.dompe.com/media/news/story/reshaping-global-health-towards-implementation/2025-12-02https://www.dompe.com/media/news/story/the-conciliation-of-private-life-and-work/2025-12-02https://www.dompe.com/media/news/story/a-new-challenge-for-the-company-supplements-and-nutraceuticals/2025-12-02https://www.dompe.com/media/news/story/sustainability-the-key-word-of-our-future/2025-12-02https://www.dompe.com/media/news/story/diversity-in-clinical-trials-including-bipoc-clinicians-to-keep-patients-safe/2025-12-02https://www.dompe.com/media/news/story/rewarding-talent-to-embrace-inclusiveness/2025-12-02https://www.dompe.com/media/news/story/the-story-behind-a-rare-disease-drug/2025-12-02https://www.dompe.com/media/news/story/covid-19-how-our-production-plant-never-stopped/2025-12-02https://www.dompe.com/media/news/story/more-than-science-la-task-force-healthcare-life-sciences-del-b20-con-armando-testa-per-ricordare-il-ruolo-fondamentale-della-ricerca-scientifica/2025-12-02https://www.dompe.com/media/news/story/the-first-pharmaceutical-co-crystal-in-dompe-is-one-of-the-winners-the-eugenio-aringhieri-innovation-award/2025-12-02https://www.dompe.com/media/news/story/augmented-reality-is-one-of-the-winners-of-the-eugenio-aringhieri-innovation-award/2025-12-02https://www.dompe.com/media/news/story/here-s-why-a-report-on-clinical-trials-is-one-of-the-winners-of-the-eugenio-aringhieri-innovation-award-2021/2025-12-02https://www.dompe.com/media/news/story/biotech-and-ai-help-win-a-production-challenge-it-is-the-beginning-of-a-technological-revolution/2025-12-02https://www.dompe.com/media/news/press-release/from-the-eye-to-the-brain-world-s-top-scientists-gather-in-rome-to-discuss-future-of-neurotrophins-in-eye-and-brain-research/2025-12-10https://www.dompe.com/media/news/press-release/dompe-s-program-in-naion-selected-for-landmark-fda-commissioner-s-national-priority-voucher-program/2025-12-03https://www.dompe.com/media/news/press-release/dompe-farmaceutici-appoints-shannon-k-sullivan-as-chief-commercial-officer-biotech/2025-12-09https://www.dompe.com/media/news/press-release/eni-e-dompe-insieme-per-attivita-di-ricerca-nell-ambito-salute/2025-12-03https://www.dompe.com/media/news/press-release/dompe-farmaceutici-and-farmamondo-group-extend-their-distribution-partnership-for-oxervate/2025-12-03https://www.dompe.com/media/news/press-release/dompe-foundation-doubles-its-funding-for-rita-levi-montalcini-fellowships-in-neuroscience-and-neurobiology/2025-12-03https://www.dompe.com/media/news/press-release/new-data-reveal-role-of-sars-cov-2-spike-protein-in-covid-19-associated-coagulopathy/2025-12-03https://www.dompe.com/media/news/press-release/dompe-first-user-of-the-leonardo-supercomputer-the-first-technology-transfer-agreement-is-to-accelerate-life-sciences-with-the-exscalate-platform/2025-12-03https://www.dompe.com/media/news/press-release/new-published-data-point-to-spike-protein-interactions-with-estrogen-receptors-as-a-cause-for-coagulopathy-in-covid-19-patients-signaling-sex-effects-and-a-path-to-improved-vaccines/2025-12-03https://www.dompe.com/media/news/press-release/searching-for-the-light-when-darkness-falls-the-challenge-of-rare-eye-diseases-becomes-a-short-film-with-the-fightforlight-campaign/2025-12-03https://www.dompe.com/media/news/press-release/cenegermin-eye-drops-receive-european-union-approval-the-first-biotechnological-drug-resulting-from-dompe-research-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-is-made-in-italy/2025-12-03https://www.dompe.com/media/news/press-release/dompe-receives-positive-chmp-opinion-in-europe-for-oxervater/2025-12-03https://www.dompe.com/media/news/press-release/a-focus-on-well-being-and-ongoing-prevention-dompes-commitment-to-athletes/2025-12-03https://www.dompe.com/media/news/press-release/dompe-announces-the-untimely-death-of-its-chief-executive-officer-eugenio-aringhieri/2025-12-03https://www.dompe.com/media/news/press-release/dompe-to-present-phase-ii-clinical-data-for-ladarixin-in-new-onset-type-1-diabetes-t1d-at-the-american-diabetes-associations-scientific-sessions/2025-12-03https://www.dompe.com/media/news/press-release/dompe-receives-industry-innovation-award-from-the-national-organization-for-rare-disorders-for-the-development-of-oxervatetm-eye-drops-cenegermin-bkbj-for-neurotrophic-keratitis/2025-12-03https://www.dompe.com/media/news/press-release/exscalate4cov-performed-in-italy-the-most-complex-supercomputing-experiment-to-identify-new-therapies-against-sars-cov2-virus/2025-12-02https://www.dompe.com/media/news/press-release/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2/2025-12-03https://www.dompe.com/media/news/press-release/exscalate-epidemics-exscalate-is-the-worlds-most-powerful-supercomputing-platform/2025-12-03https://www.dompe.com/media/news/press-release/ligate-new-european-backed-effort-against-pandemics-kicks-off-with-59-mln-euro/2025-12-03https://www.dompe.com/media/news/press-release/italian-researchers-abroad-and-a-startup-from-rome-win-the-first-call-for-ideas-by-dompe-the-selected-projects-concern-ophthalmology-and-the-wellness-area/2025-12-03https://www.dompe.com/media/news/press-release/3-clinical-trial-of-dompes-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia/2025-12-02https://www.dompe.com/media/news/press-release/molmed-and-dompe-signed-strategic-commercialization-and-supply-agreements-for-zalmoxisr-in-europe/2025-12-03https://www.dompe.com/media/news/press-release/exscalate4cov-eus-supercomputing-and-life-science-champions-gear-up-to-fight-coronavirus-pandemic/2025-12-03https://www.dompe.com/media/news/press-release/dompe-announces-zalmoxisr-product-launch-in-germany/2025-12-03https://www.dompe.com/media/news/press-release/dompe-launches-first-biotechnological-therapy-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-in-germany/2025-12-03https://www.dompe.com/media/news/press-release/dompe-completed-investments-cycle-for-expansion-of-the-production-research-and-development-site-in-laquila/2025-12-03https://www.dompe.com/media/news/press-release/exscalate4cov-italian-medicines-agency-aifa-authorizes-raloxifene-clinical-trial-for-paucisymptomatic-covid-19-patients-treated-at-home-and-in-medical-facilities/2025-12-03https://www.dompe.com/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-ladarixin-an-oral-investigational-cxcr1-2-inhibitor-in-new-onset-type-1-diabetes-t1d/2025-12-03https://www.dompe.com/media/news/press-release/dompe-announces-results-of-phase-2-study-evaluating-the-efficacy-and-safety-of-reparixin-in-patients-with-severe-covid-19-pneumonia/2025-12-03https://www.dompe.com/media/news/press-release/dompe-and-the-farmamondo-group-exsclusive-agreement-to-distribute-oxervatetm-in-russia-and-other-cis-countries/2025-12-03https://www.dompe.com/media/news/press-release/project-neon-is-underway-in-lombardy-the-public-and-private-sector-have-come-together-to-meet-the-needs-of-those-suffering-from-diseases-of-the-nervous-system-and-tumours-with-a-high-need-for-treatment/2025-12-03https://www.dompe.com/media/news/press-release/dompe-receives-fda-approval-cenegermin-eye-drops-first-in-class-recombinant-human-nerve-growth-factor-with-potential-to-completely-heal-rare-neurotrophic-keratitis/2025-12-03https://www.dompe.com/media/news/press-release/friliverr-sport-is-an-official-partner-of-the-federazione-italiana-triathlon/2025-12-03https://www.dompe.com/media/news/press-release/european-and-south-korean-agreement-signed-on-joint-development-of-a-covid-19-treatment-using-raloxifene/2025-12-03https://www.dompe.com/media/news/press-release/dompe-substipharm-agreement-for-the-sale-of-6-brands/2025-12-03https://www.dompe.com/media/news/press-release/covid-19-brazilian-health-regulatory-agency-anvisa-authorizes-dompes-repavid-19-a-phase-2-clinical-trial-for-treatment-of-severe-patients/2025-12-03https://www.dompe.com/media/news/press-release/connectivity-specialisation-and-network-these-are-the-things-that-italians-want-from-the-pharmacy-of-the-future/2025-12-03https://www.dompe.com/media/news/press-release/dompe-further-elevates-commitment-to-ophthalmics-with-industry-leading-hires/2025-12-03https://www.dompe.com/media/news/press-release/the-galien-foundation-debuts-2019-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories/2025-12-03https://www.dompe.com/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2025-12-03https://www.dompe.com/media/news/press-release/dompe-farmaceutici-spa-announces-strategic-investment-and-collaboration-with-engitix-positioned-around-use-of-dompes-exscalate-drug-discovery-platform/2025-12-02https://www.dompe.com/media/news/press-release/leonardo-and-dompe-launch-the-first-national-digital-health-security-infrastructure-with-cloud-architecture/2025-12-03https://www.dompe.com/media/news/press-release/exscalate4cov-supercomputing-platform-wins-3-million-euro-eu-funding-to-hunt-for-new-drugs-against-coronavirus-pandemic/2025-12-03https://www.dompe.com/media/news/press-release/two-clinical-studies-to-treat-mild-to-moderate-covid-19-at-home-reveal-value-of-exscalate-dompes-ai-platform-for-drug-design/2025-12-03https://www.dompe.com/media/news/press-release/dompe-announces-activation-of-u-s-clinical-trial-sites-for-phase-3-study-of-reparixin-an-oral-investigational-cxcr1-cxcr2-inhibitor-in-hospitalized-patients-with-severe-covid-19-pneumonia/2025-12-09https://www.dompe.com/media/news/press-release/dompe-doses-first-patients-in-europe-and-us-in-phase-3-study-of-isocyclosporin-for-atopic-keratoconjunctivitis/2025-12-16https://www.dompe.com/media/news/press-release/dompe-announces-first-patient-enrolled-in-new-study-of-intranasal-ngf-in-cerebral-palsy/2026-04-08https://www.dompe.com/media/news/press-release/dompe-doses-first-patient-in-phase-3-study-of-cenegermin-bkbj-in-pced/2026-06-09https://www.dompe.com/media/press/2026-06-10https://www.dompe.com/careers/2025-12-02https://www.dompe.com/careers/people-and-culture/2026-06-12https://www.dompe.com/careers/join-us/2026-06-12https://www.dompe.com/holdings/2026-03-10https://www.dompe.com/pharmacovigilance-and-vigilance/2026-06-12https://www.dompe.com/contact/2026-05-08https://www.dompe.com/privacy-policy/2025-12-02https://www.dompe.com/terms-of-service/2026-03-10https://www.dompe.com/cookie-policy/2025-12-02https://www.dompe.com/supplier-customer-information/2025-12-02https://www.dompe.com/accessibility/2026-06-11https://www.dompe.com/quality-complaint/2026-05-08https://www.dompe.com/medical-information/2026-05-08https://www.dompe.com/privacy-notice-product-quality-complaints/2025-12-02https://www.dompe.com/personal-data-notice-pharmacovigilance/2025-12-02https://www.dompe.com/personal-data-notice-pharmacovigilance-albanian-territory/2025-12-02https://www.dompe.com/404/2025-12-02https://www.dompe.com/search/2025-12-02https://www.dompe.com/whistleblowing/2025-12-02https://www.dompe.com/managed-access-programs-privacy-policy/2025-12-02https://www.dompe.com/personal-data-notice-pharmacovigilance-switzerland-territory/2026-02-09https://www.dompe.com/content/dompefarmaceutici/it.html2025-12-02https://www.dompe.com/it/2026-06-08https://www.dompe.com/it/about-us/2026-06-12https://www.dompe.com/it/about-us/chi-siamo/2026-01-13https://www.dompe.com/it/about-us/chi-siamo/storia/2026-01-13https://www.dompe.com/it/about-us/chi-siamo/management-team/2025-12-02https://www.dompe.com/it/about-us/chi-siamo/management-team/leadership/sergio-dompe/2025-12-03https://www.dompe.com/it/about-us/chi-siamo/management-team/leadership/nathalie-dompe/2025-12-02https://www.dompe.com/it/about-us/chi-siamo/management-team/innovation/shannon-k--sullivan/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/innovation/marcello-allegretti/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/innovation/ahmed-enayetallah/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/business-and-operation/marc-kubasak/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/business-and-operation/davide-polimeni/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/business-and-operation/stefano-arena/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/business-and-operation/gianluca-rossetti/2026-02-06https://www.dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/giuseppe-andreano/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/andrea-astolfi/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/monica-fantino/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/guido-romeo/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/daniele-rizzo/2025-12-02https://www.dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/sheila-folayan/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/marco-radice/2025-12-04https://www.dompe.com/it/about-us/chi-siamo/ambiente-qualita-e-sicurezza/2026-06-12https://www.dompe.com/it/about-us/chi-siamo/etica-e-trasparenza/2026-06-08https://www.dompe.com/it/about-us/chi-siamo/tax-compliance/2025-12-02https://www.dompe.com/it/about-us/dove-siamo/2026-06-12https://www.dompe.com/it/about-us/dove-siamo/produzione-biotech/2026-06-12https://www.dompe.com/it/about-us/dove-siamo/produzione-pharma/2026-06-12https://www.dompe.com/it/about-us/dove-siamo/uffici/2026-02-04https://www.dompe.com/it/science/2025-12-02https://www.dompe.com/it/science/nerve-growth-factor/2026-06-12https://www.dompe.com/it/science/pipeline/2026-06-12https://www.dompe.com/it/science/disease-focus/2025-12-02https://www.dompe.com/it/science/disease-focus/cheratite-neurotrofica/2026-06-12https://www.dompe.com/it/science/disease-focus/neuropatia-ottica-ischemica-anteriore-non-arteritica/2026-06-12https://www.dompe.com/it/science/disease-focus/cheratocongiuntivite-atopica/2026-06-12https://www.dompe.com/it/science/disease-focus/paralisi-cerebrale-infantile/2026-06-12https://www.dompe.com/it/science/disease-focus/difetto-epiteliale-corneale-persistente/2026-06-12https://www.dompe.com/it/science/exscalate/2026-06-12https://www.dompe.com/it/science/progetti-finanziati/2026-05-04https://www.dompe.com/it/medicines/2025-12-02https://www.dompe.com/it/medicines/oftalmologia/2026-03-10https://www.dompe.com/it/medicines/primary-and-specialty-care/2025-12-02https://www.dompe.com/it/medicines/primary-and-specialty-care/infiammazione-e-dolore/2026-06-12https://www.dompe.com/it/medicines/primary-and-specialty-care/tosse-e-raffreddore/2026-04-28https://www.dompe.com/it/medicines/primary-and-specialty-care/gastro/2026-04-28https://www.dompe.com/it/medicines/primary-and-specialty-care/cardiovascolare/2026-06-12https://www.dompe.com/it/medicines/primary-and-specialty-care/eye-skin-and-oral-care/2026-04-28https://www.dompe.com/it/medicines/primary-and-specialty-care/prevenzione/2026-03-10https://www.dompe.com/it/medicines/ipertensione-arteriosa-polmonare/2026-06-12https://www.dompe.com/it/media/2025-12-02https://www.dompe.com/it/media/news/2025-12-02https://www.dompe.com/it/media/news/story/fabbriche-aperte-dompe-accoglie-i-talenti-di-domani-per-un-viaggio-tra-ricerca-innovazione-e-made-in-italy/2025-12-02https://www.dompe.com/it/media/news/story/per-un-economia-della-conoscenza-fondazione-dompe-rafforza-il-sostegno-a-pavia-con-tre-borse-di-studio-dedicate-ai-dottorandi/2025-12-02https://www.dompe.com/it/media/news/story/industria-del-talento-un-ponte-tra-scuola-e-industria-farmaceutica-il-futuro-comincia-a-l-aquila/2025-12-02https://www.dompe.com/it/media/news/story/primary-care-dompe-tre-prodotti-di-automedicazione-al-top/2025-12-02https://www.dompe.com/it/media/news/story/produzione-sciroppi-e-colluttori-al-via-la-nuova-linea-nello-stabilimento-de-l-aquila/2025-12-02https://www.dompe.com/it/media/news/story/ricerca-traslazionale-sulle-neurotrofine-dalla-cornea-al-sistema-nervoso-centrale/2025-12-02https://www.dompe.com/it/media/news/story/open-factory-in-dompe-porte-aperte-ai-giovani/2025-12-02https://www.dompe.com/it/media/news/story/intervista-a-sergio-dompe-l-ai-una-grande-risorsa-per-spingere-il-made-in-italy-ma-serve-piu-formazione/2025-12-02https://www.dompe.com/it/media/news/story/unleashing-innovation-dompe-s-journey-into-the-digital-age-of-pharma/2025-12-02https://www.dompe.com/it/media/news/story/rare-disease-day-2024/2025-12-02https://www.dompe.com/it/media/news/story/investire-nella-formazione-ho-acquisito-preziose-informazioni-per-aiutare-il-mio-team-a-rispettare-le-scadenze-fondamentali-per-gli-studi-clinici/2025-12-02https://www.dompe.com/it/media/news/story/la-futura-generazione-delle-life-science/2025-12-02https://www.dompe.com/it/media/news/story/tg1-il-capo-dello-stato-ha-incontrato-i-vincitori-del-premio-leonardo-che-seleziona-le-eccellenze-del-paese-in-diversi-settori/2025-12-02https://www.dompe.com/it/media/news/story/exscalate-meet-our-partners-pieter-stouten-consulente-tecnologie-computazionali/2025-12-02https://www.dompe.com/it/media/news/story/exscalate-meet-our-partners-giulio-vistoli-professore-ordinario-di-chimica-farmaceutica-universita-degli-studi-di-milano/2025-12-02https://www.dompe.com/it/media/news/story/exscalate-meet-our-partners-gianluca-palermo-full-professor-of-computer-engineering-at-politecnico-di-milano/2025-12-02https://www.dompe.com/it/media/news/story/exscalate-meet-our-partners-torsten-schwede-vice-president-for-research-university-of-basel/2025-12-02https://www.dompe.com/it/media/news/story/con-la-tecnologia-e-la-ricerca-vinciamo-anche-negli-stati-uniti-ma-la-produzione-e-in-italia/2025-12-02https://www.dompe.com/it/media/news/story/scopri-di-piu-sulla-fondazione-dompe-ecco-il-nuovo-video/2025-12-02https://www.dompe.com/it/media/news/story/dompe-torna-a-illuminare-la-notte-dei-ricercatori-con-sharper/2025-12-02https://www.dompe.com/it/media/news/story/dompe-illumina-la-notte-dei-ricercatori-con-sharper/2025-12-02https://www.dompe.com/it/media/news/story/the-authenticity-appreciated-by-horses-reveals-leadership-ability/2025-12-02https://www.dompe.com/it/media/news/story/scopri-la-storia-di-akash-dall-assam-a-napoli/2025-12-02https://www.dompe.com/it/media/news/story/stage-on-stage-la-parola-agli-stagisti/2025-12-02https://www.dompe.com/it/media/news/story/seminario-teta-un-opportunita-di-crescita-personale/2025-12-02https://www.dompe.com/it/media/news/story/esplorando-il-potere-della-leadership-il-progetto-mbti/2025-12-02https://www.dompe.com/it/media/news/story/equine-guided-learning-un-viaggio-alla-scoperta-delle-nostre-capacita-manageriali/2025-12-02https://www.dompe.com/it/media/news/story/l-impegno-ambientale-di-dompe-farmaceutici/2025-12-02https://www.dompe.com/it/media/news/story/celebriamo-la-diversita-e-l-inclusione-con-la-giornata-bimbi-in-dompe/2025-12-02https://www.dompe.com/it/media/news/story/we-embrace-il-nostro-impegno-per-la-scienza-nell-interesse-dei-pazienti-in-un-video/2025-12-02https://www.dompe.com/it/media/news/story/gary-pisano-il-futuro-del-settore-delle-bioscienze/2025-12-02https://www.dompe.com/it/media/news/story/l-importanza-delle-malattie-rare-la-rarita-non-deve-essere-ignorata/2025-12-02https://www.dompe.com/it/media/news/story/abbracciando-la-sfida-nella-scienza-dall-intuizione-al-futuro-dell-innovazione/2025-12-02https://www.dompe.com/it/media/news/story/l-aquila-30-anni-dopo/2025-12-02https://www.dompe.com/it/media/news/story/dompe-per-i-farmacisti-nasce-il-progetto-numbers-ideato-da-i-farma/2025-12-02https://www.dompe.com/it/media/news/story/dompe-partner-della-prima-mostra-monografica-in-usa-dedicata-al-codice-atlantico-di-leonardo-da-vinci/2025-12-02https://www.dompe.com/it/media/news/story/rafael-cypriano-dutra-uno-degli-scienziati-piu-citati-del-mondo/2025-12-02https://www.dompe.com/it/media/news/story/covid-19-ecco-come-abbiamo-garantito-la-continuita-produttiva-durante-lemergenza/2025-12-02https://www.dompe.com/it/media/news/story/la-realta-aumentata-vince-il-premio-dellinnovazione-eugenio-aringhieri/2025-12-02https://www.dompe.com/it/media/news/story/ecco-perche-un-report-sui-trial-clinici-ha-vinto-il-premio-dellinnovazione-eugenio-aringhieri-2021/2025-12-02https://www.dompe.com/it/media/news/story/exscalate-la-natura-e-scritta-in-linguaggio-matematico/2025-12-02https://www.dompe.com/it/media/news/story/giornata-internazionale-contro-la-violenza-sulle-donne-insieme-per-dire-no/2025-12-02https://www.dompe.com/it/media/news/story/come-nasce-un-farmaco-per-una-malattia-rara/2025-12-02https://www.dompe.com/it/media/news/story/biotech-e-ai-aiutano-a-vincere-una-sfida-produttiva-e-linizio-di-una-rivoluzione-tecnologica/2025-12-02https://www.dompe.com/it/media/news/story/trasparenza-nel-mondo-healthcare-una-legge-di-cui-il-nostro-paese-ha-bisogno/2025-12-02https://www.dompe.com/it/media/news/story/una-nuova-sfida-per-lazienda-lintegrazione-e-la-nutraceutica/2025-12-02https://www.dompe.com/it/media/news/story/distinguere-tra-ricerca-di-base-e-applicata-non-ha-senso/2025-12-02https://www.dompe.com/it/media/news/story/sostenibilita-una-parola-che-e-anche-una-promessa/2025-12-02https://www.dompe.com/it/media/news/story/la-conciliazione-tra-vita-privata-e-lavoro/2025-12-02https://www.dompe.com/it/media/news/story/exscalate4cov-is-now-a-book-on-high-performance-computing-for-covid-drug-discovery/2025-12-02https://www.dompe.com/it/media/news/story/il-primo-co-cristallo-farmaceutico-dompe-vince-il-premio-dellinnovazione-eugenio-aringhieri/2025-12-02https://www.dompe.com/it/media/news/story/more-than-science-la-task-force-healthcare-and-life-sciences-del-b20-con-armando-testa-per-ricordare-il-ruolo-fondamentale-della-ricerca-scientifica/2025-12-02https://www.dompe.com/it/media/news/story/clinical-trial-piu-inclusivi-aumentare-la-diversity-per-proteggere-i-pazienti/2025-12-02https://www.dompe.com/it/media/news/story/premiare-il-talento-per-diventare-piu-inclusivi/2025-12-02https://www.dompe.com/it/media/news/story/i-supercomputer-al-servizio-della-drug-discovery-ecco-come-e-nato-exscalate/2025-12-02https://www.dompe.com/it/media/news/story/dialogo-b20-g20-sulla-salute-e-le-scienze-della-vita/2025-12-02https://www.dompe.com/it/media/news/story/studi-clinici-digitali/2025-12-02https://www.dompe.com/it/media/news/story/exscalate-il-futuro-e-gia-qui/2025-12-02https://www.dompe.com/it/media/news/story/la-scienza-alla-base-della-linea-bioritmon-firmata-dompe-farmaceutici-dalla-creazione-del-prodotto-alla-campagna-marketing/2025-12-02https://www.dompe.com/it/media/news/story/collaborare-per-innovare/2025-12-02https://www.dompe.com/it/media/news/story/la-trasformazione-passa-dal-digitale/2025-12-02https://www.dompe.com/it/media/news/story/la-sicurezza-digitale/2025-12-02https://www.dompe.com/it/media/news/story/dalla-danimarca-alla-spagna-e-allitalia-il-percorso-di-un-ricercatore/2025-12-02https://www.dompe.com/it/media/news/story/innovare-per-crescere-dalle-malattie-rare-al-covid/2025-12-02https://www.dompe.com/it/media/news/story/regulatory-affairs-leffetto-covid-19-e-solo-temporaneo/2025-12-02https://www.dompe.com/it/media/news/story/un-camp-per-la-formazione-in-digital-marketing/2025-12-02https://www.dompe.com/it/media/news/story/la-dompe-di-domani/2025-12-02https://www.dompe.com/it/media/news/story/piattaforma-tecnologica-integrata-per-lidentificazione-e-lo-sviluppo-di-nuovi-farmaci-per-il-trattamento-di-patologie-rare-o-ad-elevato-bisogno-di-cura-insoddisfatto/2025-12-02https://www.dompe.com/it/media/news/story/la-sicurezza-sul-lavoro-e-piu-digitalizzata-che-mai/2025-12-02https://www.dompe.com/it/media/news/press-release/industria-del-talento-il-progetto-di-dompe-e-un-ponte-tra-studenti-e-industria-farmaceutica/2025-12-04https://www.dompe.com/it/media/news/press-release/from-the-eye-to-the-brain/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-farmaceutici-nomina-shannon-k-sullivan-come-chief-commercial-officer-biotech/2025-12-16https://www.dompe.com/it/media/news/press-release/il-programma-di-ricerca-di-dompe-farmaceutici-per-la-naion-e-stato-selezionato-per-l-iniziativa-landmark-fda-il-commissioner-s-national-priority-voucher-program/2025-12-04https://www.dompe.com/it/media/news/press-release/eni-e-dompe-insieme-per-attivita-di-ricerca-nell-ambito-salute/2025-12-04https://www.dompe.com/it/media/news/press-release/univaq-e-dompe-insieme-per-la-formazione-dei-talenti-nell-industria-delle-life-sciences/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-farmaceutici-il-nuovo-posizionamento-globale-parte-da-ricerca-e-digitale-ed-e-firmato-edelman/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-foundation-doubles-its-funding-for-rita-levi-montalcini-fellowships-in-neuroscience-and-neurobiology/2025-12-04https://www.dompe.com/it/media/news/press-release/covid-19-indicazioni-per-i-vaccini-di-nuova-generazione-da-studio-sul-ruolo-della-proteina-spike-di-sars-cov-2-nelle-coagulopatie/2025-12-03https://www.dompe.com/it/media/news/press-release/progetto-di-supercomputing-exscalate4cov-raloxifene-farmaco-candidato-per-contrastare-il-virus-sars-cov-2/2025-12-04https://www.dompe.com/it/media/news/press-release/ligate-new-european-backed-effort-against-pandemics-kicks-off-with-5-9-mln/2025-12-04https://www.dompe.com/it/media/news/press-release/the-galien-foundation-debuts-2019-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories/2025-12-04https://www.dompe.com/it/media/news/press-release/ricercatori-italiani-allestero-e-una-startup-romana-si-aggiudicano-la-prima-call-for-ideas-di-dompe-i-progetti-selezionati-riguardano-loftalmologia-e-larea-benessere/2025-12-04https://www.dompe.com/it/media/news/press-release/tra-like-ed-e-commerce-quali-modelli-per-la-farmacia-di-domani/2025-12-04https://www.dompe.com/it/media/news/press-release/molmed-e-dompe-stipulano-un-accordo-strategico-per-la-commercializzazione-e-la-fornitura-di-zalmoxis-in-europa/2025-12-04https://www.dompe.com/it/media/news/press-release/premi-di-laurea-2018-dompe-farmaceutici-e-comitato-leonardo-premiano-la-migliore-tesi-sugli-effetti-degli-amminoacidi-ramificati-sul-metabolismo-umano/2025-12-04https://www.dompe.com/it/media/news/press-release/nuove-terapie-e-meno-costi-per-la-sanita-con-i-farmaci-gia-approvati-parte-il-progetto-europeo-remedi4all/2025-12-04https://www.dompe.com/it/media/news/press-release/linnovazione-diventa-realta-al-via-a-milano-frilivertherace-la-prima-competizione-nazionale-di-triathlon-indoor/2025-12-04https://www.dompe.com/it/media/news/press-release/la-ricerca-della-luce-quando-scende-loscurita-la-sfida-alle-malattie-rare-degli-occhi-diventa-un-cortometraggio-con-la-campagna-fightforlight/2025-12-04https://www.dompe.com/it/media/news/press-release/leonardo-e-dompe-nasce-la-prima-infrastruttura-nazionale-di-sicurezza-sanitaria-digitale-con-architettura-cloud/2025-12-04https://www.dompe.com/it/media/news/press-release/nota-stampa-dompe-farmaceutici-dissociazione-da-messaggio-diffuso-via-social-media-relativo-ad-utilizzo-cebion/2025-12-04https://www.dompe.com/it/media/news/press-release/la-collaborazione-trasforma-la-ricerca-in-business/2025-12-04https://www.dompe.com/it/media/news/press-release/il-consorzio-exscalate4cov-progetto-di-riferimento-in-europa-per-contrastare-il-coronavirus-con-il-supercalcolo/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-farmaceutici-anche-la-food-and-drug-administration-approva-cenegermin-gocce-oculari-per-il-trattamento-della-cheratite-neurotrofica-frutto-della-ricerca-dompe/2025-12-03https://www.dompe.com/it/media/news/press-release/exscalate4cov-il-supercalcolo-e-le-eccellenze-delle-life-sciences-europee-in-campo-contro-il-coronavirus/2025-12-04https://www.dompe.com/it/media/news/press-release/exscalate4cov-eseguito-in-italia-lesperimento-di-supercalcolo-piu-complesso-mai-realizzato-al-mondo-per-identificare-nuove-terapie-contro-il-virus-sars-cov2/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-riceve-opinione-positiva-del-chmp-in-europa-per-oxervate/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-substipharm-agreement-for-the-sale-of-6-brands/2025-12-04https://www.dompe.com/it/media/news/press-release/lagenzia-brasiliana-del-farmaco-anvisa-autorizza-dompe-alla-sperimentazione-clinica-in-fase-2-di-reparixin-su-pazienti-covid-19-gravi/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-completato-ciclo-di-investimenti-per-lampliamento-del-sito-di-produzione-e-ricerca-e-sviluppo-dellaquila/2025-12-03https://www.dompe.com/it/media/news/press-release/connessione-specializzazione-e-network-ecco-cosa-chiedono-gli-italiani-alla-farmacia-del-futuro/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-farmaceutici-al-via-sidebyside4innovation-il-contest-volto-a-supportare-i-progetti-di-innovazione-in-oftalmologia-e-nutrizione/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-announces-results-of-phase-2-study-evaluating-the-efficacy-and-safety-of-reparixin-in-patients-with-severe-covid-19-pneumonia/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-farmaceutici-e-comitato-leonardo-premiano-la-migliore-tesi-sui-meccanismi-alla-base-dello-sviluppo-della-fatigue-in-pazienti-oncologici/2025-12-03https://www.dompe.com/it/media/news/press-release/exscalate-frutto-della-collaborazione-tra-dompe-farmaceutici-politecnico-di-milano-e-cineca-e-italiano-il-supercalcolo-intelligente-piu-potente-e-a-basso-costo-al-mondo-a-supporto-della-ricerca-di-terapie-in-caso-di-epidemie/2025-12-02https://www.dompe.com/it/media/news/press-release/cxcr2-inhibitor-in-hospitalized-patients-with-severe-covid-19-pneumonia/2025-12-03https://www.dompe.com/it/media/news/press-release/due-nuovi-studi-italia-usa-indicano-nelle-interazioni-della-proteina-spike-con-i-recettori-degli-estrogeni-la-causa-della-coagulopatia-nei-pazienti-covid-19-indicazioni-per-migliorare-la-prossima-generazione-di-vaccini-anti-covid/2025-12-02https://www.dompe.com/it/media/news/press-release/al-via-il-progetto-neon-pubblico-e-privato-si-alleano-in-lombardia-per-rispondere-ai-bisogni-di-chi-soffre-di-malattie-del-sistema-nervoso-e-tumori-ad-elevato-bisogno-di-cura/2025-12-03https://www.dompe.com/it/media/news/press-release/farmacisti-a-scuola-di-futuro-digitale-parte-da-napoli-liniziativa-itinerante-firmata-dompe/2025-12-04https://www.dompe.com/it/media/news/press-release/cenegermin-collirio-soluzione-riceve-lapprovazione-europea-e-made-in-italy-il-primo-farmaco-biotecnologico-frutto-della-ricerca-dompe-per-il-trattamento-della-cheratite-neurotrofica-moderata-o-grave/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-announces-zalmoxis-product-launch-in-germany/2025-12-03https://www.dompe.com/it/media/news/press-release/european-and-south-korean-agreement-signed-on-joint-development-of-a-covid-19-treatment-using-raloxifene/2025-12-04https://www.dompe.com/it/media/news/press-release/due-studi-clinici-per-il-trattamento-domiciliare-del-covid-19-da-lieve-a-moderato-confermano-il-valore-di-exscalate-la-piattaforma-ai-di-dompe-per-il-drug-design/2025-12-04https://www.dompe.com/it/media/news/press-release/exscalate4cov-via-libera-da-aifa-ad-avvio-studio-clinico-su-raloxifene-per-il-trattamento-di-pazienti-covid-paucisintomatici-ospedalizzati-o-a-domicilio/2025-12-04https://www.dompe.com/it/media/news/press-release/2-inhibitor-in-new-onset-type-1-diabetes-t1d/2025-12-02https://www.dompe.com/it/media/news/press-release/3-clinical-trial-of-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-investimenti-strategici-e-collaborazione-con-engitix-per-luso-di-exscalate-la-piattaforma-di-intelligenza-artificiale-per-la-drug-discovery/2025-12-04https://www.dompe.com/it/media/news/press-release/friliver-sport-e-partner-ufficiale-della-federazione-italiana-triathlon/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-launches-first-biotechnological-therapy-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-in-germany/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-primo-utente-del-supercomputer-leonardo-con-la-piattaforma-exscalate/2025-12-04https://www.dompe.com/it/media/news/press-release/attenzione-al-benessere-e-prevenzione-continua-limpegno-dompe-al-fianco-dello-sportivo/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-farmaceutici-continuiamo-ad-assumere-e-investire-per-mantenere-eccellenza-e-competitivita/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-farmaceutici-annuncia-la-prematura-scomparsa-dellad-eugenio-aringhieri/2025-12-03https://www.dompe.com/it/media/news/press-release/comunicazione-partecipazione-al-capitale-sociale-di-philogen-s-p-a/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-further-elevates-commitment-to-ophthalmics-with-industry-leading-hires/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-and-the-farmamondo-group-exsclusive-agreement-to-distribute-oxervate-in-russia-and-other-cis-countries/2025-12-03https://www.dompe.com/it/media/news/press-release/dompe-receives-industry-innovation-award-from-the-national-organization-for-rare-disorders-for-the-development-of-oxervatetm-eye-drops-cenegermin-bkbj-for-neurotrophic-keratitis/2025-12-04https://www.dompe.com/it/media/news/press-release/dompe-avvia-la-somministrazione-ai-primi-pazienti-in-europa-e-stati-uniti-nello-studio-di-fase-3-con-isociclosporina-nella-cheratocongiuntivite-atopica/2025-12-16https://www.dompe.com/it/media/news/press-release/dompe-farmaceutici-arruolato-il-primo-paziente-nello-studio-per-il-trattamento-della-paralisi-cerebrale-infantile-con-somministrazione-intranasale-di-ngf/2026-03-30https://www.dompe.com/it/media/news/press-release/industria-del-talento-2026-al-via-il-secondo-anno-del-progetto-dompe-che-connette-scuola-secondaria-e-farmaceutica/2026-06-08https://www.dompe.com/it/media/news/press-release/industria-del-talento-2026-al-via-il-secondo-anno-del-progetto-dompe-che-connette-scuola-secondaria-e-farmaceutica0/2026-06-08https://www.dompe.com/it/media/press/2026-06-10https://www.dompe.com/it/careers/2025-12-02https://www.dompe.com/it/careers/people-and-culture/2026-06-12https://www.dompe.com/it/careers/lavora-con-noi/2026-06-12https://www.dompe.com/it/holdings/2026-03-10https://www.dompe.com/it/farmacovigilanza-e-vigilanza/2026-06-12https://www.dompe.com/it/contatti/2026-05-08https://www.dompe.com/it/informativa-privacy/2025-12-02https://www.dompe.com/it/condizioni-di-utilizzo/2026-03-10https://www.dompe.com/it/informativa-cookie/2025-12-02https://www.dompe.com/it/informativa-clienti-e-fornitori/2025-12-02https://www.dompe.com/it/accessibilit%C3%A0/2026-03-10https://www.dompe.com/it/reclami-di-qualita/2026-05-08https://www.dompe.com/it/informazione-medica/2026-05-08https://www.dompe.com/it/informativa-privacy%20-reclami-sulla-qualit%C3%A0-di-prodotto/2025-12-02https://www.dompe.com/it/politica-sul-trattamento-dei-dati-relativi-alla-farmacovigilanza/2025-12-02https://www.dompe.com/it/404/2025-12-02https://www.dompe.com/it/search/2025-12-02https://www.dompe.com/it/whistleblowing/2025-12-02https://www.dompe.com/content/dompefarmaceutici/us.html2025-12-02https://www.dompe.com/us/2026-06-09https://www.dompe.com/us/about-us/2026-06-12https://www.dompe.com/us/about-us/who-we-are/2026-01-13https://www.dompe.com/us/about-us/who-we-are/history/2026-01-13https://www.dompe.com/us/about-us/who-we-are/management-team/2025-12-02https://www.dompe.com/us/about-us/who-we-are/management-team/leadership/sergio-dompe/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/leadership/nathalie-dompe/2025-12-02https://www.dompe.com/us/about-us/who-we-are/management-team/innovation/shannon-k--sullivan/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/innovation/marcello-allegretti/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/innovation/ahmed-enayetallah/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/business-and-operation/marc-kubasak/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/business-and-operation/davide-polimeni/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/business-and-operation/stefano-arena/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/business-and-operation/gianluca-rossetti/2026-02-06https://www.dompe.com/us/about-us/who-we-are/management-team/enabling-functions/giuseppe-andreano/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/enabling-functions/andrea-astolfi/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/enabling-functions/monica-fantino/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/enabling-functions/guido-romeo/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/enabling-functions/daniele-rizzo/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/enabling-functions/sheila-folayan/2025-12-03https://www.dompe.com/us/about-us/who-we-are/management-team/enabling-functions/marco-radice/2025-12-03https://www.dompe.com/us/about-us/who-we-are/environment-quality-and-safety/2026-06-12https://www.dompe.com/us/about-us/who-we-are/ethics-and-compliance/2026-06-12https://www.dompe.com/us/about-us/who-we-are/grants-and-donations/2026-03-10https://www.dompe.com/us/about-us/where-we-are/2026-06-12https://www.dompe.com/us/about-us/where-we-are/manufacturing-biotech/2026-06-12https://www.dompe.com/us/about-us/where-we-are/manufacturing-pharma/2026-06-12https://www.dompe.com/us/about-us/where-we-are/offices/2026-02-04https://www.dompe.com/us/science/2025-12-02https://www.dompe.com/us/science/nerve-growth-factor/2026-06-12https://www.dompe.com/us/science/pipeline/2026-06-12https://www.dompe.com/us/science/disease-focus/2025-12-02https://www.dompe.com/us/science/disease-focus/neurotrophic-keratitis/2026-06-12https://www.dompe.com/us/science/disease-focus/non-arteritic-anterior-ischemic-optic-neuropathy/2026-06-12https://www.dompe.com/us/science/disease-focus/atopic-keratoconjunctivitis/2026-06-12https://www.dompe.com/us/science/disease-focus/cerebral-palsy/2026-06-12https://www.dompe.com/us/science/disease-focus/persistent-corneal-epithelial-defect/2026-06-12https://www.dompe.com/us/science/exscalate/2026-06-12https://www.dompe.com/us/medicines/2025-12-02https://www.dompe.com/us/medicines/ophthalmics/2026-06-12https://www.dompe.com/us/media/2025-12-02https://www.dompe.com/us/media/news/2025-12-02https://www.dompe.com/us/media/news/story/translational-research-on-neurotrophins-from-corneal-disease-to-the-central-nervous-system/2025-12-02https://www.dompe.com/us/media/news/story/why-early-detection-of-neurotrophic-keratitis-is-crucial/2025-12-02https://www.dompe.com/us/media/news/story/rare-disease-day-2024/2025-12-02https://www.dompe.com/us/media/news/story/investing-in-training-i-ve-gained-valuable-insights-to-help-my-team-meet-key-timelines-for-clinical-trials/2025-12-02https://www.dompe.com/us/media/news/story/the-future-generation-of-life-sciences/2025-12-02https://www.dompe.com/us/media/news/story/the-dompe-foundation-kicks-off-the-2023-2024-program-with-44-scholarship-in-us-and-italy/2025-12-02https://www.dompe.com/us/media/news/story/discover-more-about-the-dompe-foundation-here-s-the-new-video/2025-12-02https://www.dompe.com/us/media/news/story/mbti-a-leadership-that-thrives-in-diversity/2025-12-02https://www.dompe.com/us/media/news/story/equine-guided-learning-a-journey-of-self-discovery-to-empower-managers-with-leadership-skills/2025-12-02https://www.dompe.com/us/media/news/story/dompe-pharmaceuticals-environmental-commitment/2025-12-02https://www.dompe.com/us/media/news/story/we-embrace-discover-our-commitment-to-science-in-the-interest-of-patients/2025-12-02https://www.dompe.com/us/media/news/story/gary-pisano-the-future-of-the-business-of-bioscience/2025-12-02https://www.dompe.com/us/media/news/story/the-importance-of-rare-diseases-rarity-should-not-be-ignored/2025-12-02https://www.dompe.com/us/media/news/story/l-aquila-an-increasingly-green-and-biotech-production-hub/2025-12-02https://www.dompe.com/us/media/news/story/embracing-the-challenge-in-science-from-intuition-to-the-future-of-innovation/2025-12-02https://www.dompe.com/us/media/news/story/dompe-is-a-partner-of-the-first-monographic-exhibition-in-the-usa-dedicated-to-leonardo-da-vinci-s-codex-atlanticus/2025-12-02https://www.dompe.com/us/media/news/story/exscalate4cov-is-now-a-book-on-high-performance-computing-for-covid-drug-discovery/2025-12-02https://www.dompe.com/us/media/news/story/rafael-cypriano-dutra-one-of-the-world-s-most-cited-scientists-is-in-dompe-s-labs/2025-12-02https://www.dompe.com/us/media/news/story/from-denmark-to-spain-and-italy-the-journey-of-a-researcher/2025-12-02https://www.dompe.com/us/media/news/story/the-dompe-of-tomorrow/2025-12-02https://www.dompe.com/us/media/news/story/international-day-for-the-elimination-of-violence-against-women-together-we-say-no/2025-12-02https://www.dompe.com/us/media/news/story/our-digital-transformation/2025-12-02https://www.dompe.com/us/media/news/story/integrated-technology-platform-for-the-identification-and-development-of-new-drugs-for-the-treatment-of-rare-diseases-or-diseases-with-a-high-unmet-need-for-treatment/2025-12-02https://www.dompe.com/us/media/news/story/supercomputers-at-the-service-of-drug-discovery-this-is-how-exscalate-was-born/2025-12-02https://www.dompe.com/us/media/news/story/digital-clinical-trials/2025-12-02https://www.dompe.com/us/media/news/story/digital-security/2025-12-02https://www.dompe.com/us/media/news/story/innovating-to-grow-from-rare-diseases-to-covid/2025-12-02https://www.dompe.com/us/media/news/story/exscalate-the-future-is-already-here/2025-12-02https://www.dompe.com/us/media/news/story/collaborate-to-innovate-follow-the-live-event/2025-12-02https://www.dompe.com/us/media/news/story/reshaping-global-health-towards-implementation/2025-12-02https://www.dompe.com/us/media/news/story/the-conciliation-of-private-life-and-work/2025-12-02https://www.dompe.com/us/media/news/story/a-new-challenge-for-the-company-supplements-and-nutraceuticals/2025-12-02https://www.dompe.com/us/media/news/story/sustainability-the-key-word-of-our-future/2025-12-02https://www.dompe.com/us/media/news/story/diversity-in-clinical-trials-including-bipoc-clinicians-to-keep-patients-safe/2025-12-02https://www.dompe.com/us/media/news/story/rewarding-talent-to-embrace-inclusiveness/2025-12-02https://www.dompe.com/us/media/news/story/the-story-behind-a-rare-disease-drug/2025-12-02https://www.dompe.com/us/media/news/story/covid-19-how-our-production-plant-never-stopped/2025-12-02https://www.dompe.com/us/media/news/story/more-than-science-la-task-force-healthcare-life-sciences-del-b20-con-armando-testa-per-ricordare-il-ruolo-fondamentale-della-ricerca-scientifica/2025-12-02https://www.dompe.com/us/media/news/story/the-first-pharmaceutical-co-crystal-in-dompe-is-one-of-the-winners-the-eugenio-aringhieri-innovation-award/2025-12-02https://www.dompe.com/us/media/news/story/augmented-reality-is-one-of-the-winners-of-the-eugenio-aringhieri-innovation-award/2025-12-02https://www.dompe.com/us/media/news/story/here-s-why-a-report-on-clinical-trials-is-one-of-the-winners-of-the-eugenio-aringhieri-innovation-award-2021/2025-12-02https://www.dompe.com/us/media/news/story/biotech-and-ai-help-win-a-production-challenge-it-is-the-beginning-of-a-technological-revolution/2025-12-02https://www.dompe.com/us/media/news/press-release/dompe-farmaceutici-appoints-shannon-k-sullivan-as-chief-commercial-officer-biotech/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-s-program-in-naion-selected-for-landmark-fda-commissioner-s-national-priority-voucher-program/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-foundation-doubles-its-funding-for-rita-levi-montalcini-fellowships-in-neuroscience-and-neurobiology/2025-12-03https://www.dompe.com/us/media/news/press-release/new-data-reveal-role-of-sars-cov-2-spike-protein-in-covid-19-associated-coagulopathy/2025-12-03https://www.dompe.com/us/media/news/press-release/new-published-data-point-to-spike-protein-interactions-with-estrogen-receptors-as-a-cause-for-coagulopathy-in-covid-19-patients-signaling-sex-effects-and-a-path-to-improved-vaccines/2025-12-03https://www.dompe.com/us/media/news/press-release/searching-for-the-light-when-darkness-falls-the-challenge-of-rare-eye-diseases-becomes-a-short-film-with-the-fightforlight-campaign/2025-12-03https://www.dompe.com/us/media/news/press-release/cenegermin-eye-drops-receive-european-union-approval-the-first-biotechnological-drug-resulting-from-dompe-research-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-is-made-in-italy/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-receives-positive-chmp-opinion-in-europe-for-oxervater/2025-12-03https://www.dompe.com/us/media/news/press-release/a-focus-on-well-being-and-ongoing-prevention-dompes-commitment-to-athletes/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-announces-the-untimely-death-of-its-chief-executive-officer-eugenio-aringhieri/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-to-present-phase-ii-clinical-data-for-ladarixin-in-new-onset-type-1-diabetes-t1d-at-the-american-diabetes-associations-scientific-sessions/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-receives-industry-innovation-award-from-the-national-organization-for-rare-disorders-for-the-development-of-oxervatetm-eye-drops-cenegermin-bkbj-for-neurotrophic-keratitis/2025-12-03https://www.dompe.com/us/media/news/press-release/exscalate4cov-performed-in-italy-the-most-complex-supercomputing-experiment-to-identify-new-therapies-against-sars-cov2-virus/2025-12-03https://www.dompe.com/us/media/news/press-release/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2/2025-12-03https://www.dompe.com/us/media/news/press-release/exscalate-epidemics-exscalate-is-the-worlds-most-powerful-supercomputing-platform/2025-12-03https://www.dompe.com/us/media/news/press-release/ligate-new-european-backed-effort-against-pandemics-kicks-off-with-59-mln-euro/2025-12-03https://www.dompe.com/us/media/news/press-release/italian-researchers-abroad-and-a-startup-from-rome-win-the-first-call-for-ideas-by-dompe-the-selected-projects-concern-ophthalmology-and-the-wellness-area/2025-12-03https://www.dompe.com/us/media/news/press-release/3-clinical-trial-of-dompes-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia/2025-12-02https://www.dompe.com/us/media/news/press-release/molmed-and-dompe-signed-strategic-commercialization-and-supply-agreements-for-zalmoxisr-in-europe/2025-12-03https://www.dompe.com/us/media/news/press-release/exscalate4cov-eus-supercomputing-and-life-science-champions-gear-up-to-fight-coronavirus-pandemic/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-announces-zalmoxisr-product-launch-in-germany/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-launches-first-biotechnological-therapy-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-in-germany/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-completed-investments-cycle-for-expansion-of-the-production-research-and-development-site-in-laquila/2025-12-03https://www.dompe.com/us/media/news/press-release/exscalate4cov-italian-medicines-agency-aifa-authorizes-raloxifene-clinical-trial-for-paucisymptomatic-covid-19-patients-treated-at-home-and-in-medical-facilities/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-ladarixin-an-oral-investigational-cxcr1-2-inhibitor-in-new-onset-type-1-diabetes-t1d/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-announces-results-of-phase-2-study-evaluating-the-efficacy-and-safety-of-reparixin-in-patients-with-severe-covid-19-pneumonia/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-and-the-farmamondo-group-exsclusive-agreement-to-distribute-oxervatetm-in-russia-and-other-cis-countries/2025-12-03https://www.dompe.com/us/media/news/press-release/project-neon-is-underway-in-lombardy-the-public-and-private-sector-have-come-together-to-meet-the-needs-of-those-suffering-from-diseases-of-the-nervous-system-and-tumours-with-a-high-need-for-treatment/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-receives-fda-approval-cenegermin-eye-drops-first-in-class-recombinant-human-nerve-growth-factor-with-potential-to-completely-heal-rare-neurotrophic-keratitis/2025-12-03https://www.dompe.com/us/media/news/press-release/friliverr-sport-is-an-official-partner-of-the-federazione-italiana-triathlon/2025-12-03https://www.dompe.com/us/media/news/press-release/european-and-south-korean-agreement-signed-on-joint-development-of-a-covid-19-treatment-using-raloxifene/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-substipharm-agreement-for-the-sale-of-6-brands/2025-12-03https://www.dompe.com/us/media/news/press-release/covid-19-brazilian-health-regulatory-agency-anvisa-authorizes-dompes-repavid-19-a-phase-2-clinical-trial-for-treatment-of-severe-patients/2025-12-03https://www.dompe.com/us/media/news/press-release/connectivity-specialisation-and-network-these-are-the-things-that-italians-want-from-the-pharmacy-of-the-future/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-further-elevates-commitment-to-ophthalmics-with-industry-leading-hires/2025-12-03https://www.dompe.com/us/media/news/press-release/the-galien-foundation-debuts-2019-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-farmaceutici-spa-announces-strategic-investment-and-collaboration-with-engitix-positioned-around-use-of-dompes-exscalate-drug-discovery-platform/2025-12-03https://www.dompe.com/us/media/news/press-release/leonardo-and-dompe-launch-the-first-national-digital-health-security-infrastructure-with-cloud-architecture/2025-12-03https://www.dompe.com/us/media/news/press-release/exscalate4cov-supercomputing-platform-wins-3-million-euro-eu-funding-to-hunt-for-new-drugs-against-coronavirus-pandemic/2025-12-03https://www.dompe.com/us/media/news/press-release/two-clinical-studies-to-treat-mild-to-moderate-covid-19-at-home-reveal-value-of-exscalate-dompes-ai-platform-for-drug-design/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-announces-activation-of-u-s-clinical-trial-sites-for-phase-3-study-of-reparixin-an-oral-investigational-cxcr1-cxcr2-inhibitor-in-hospitalized-patients-with-severe-covid-19-pneumonia/2025-12-03https://www.dompe.com/us/media/news/press-release/dompe-doses-first-patients-in-europe-and-us-in-phase-3-study-of-isocyclosporin-for-atopic-keratoconjunctivitis/2025-12-16https://www.dompe.com/us/media/news/press-release/dompe-announces-first-patient-enrolled-in-new-study-of-intranasal-ngf-in-cerebral-palsy/2026-03-30https://www.dompe.com/us/media/news/press-release/dompe-doses-first-patient-in-phase-3-study-of-cenegermin-bkbj-in-pced/2026-06-09https://www.dompe.com/us/media/press/2026-05-11https://www.dompe.com/us/careers/2025-12-02https://www.dompe.com/us/careers/people-and-culture/2026-06-12https://www.dompe.com/us/careers/join-us/2026-06-12https://www.dompe.com/us/pharmacovigilance-and-vigilance/2026-06-12https://www.dompe.com/us/contact/2026-05-08https://www.dompe.com/us/privacy-policy/2025-12-02https://www.dompe.com/us/terms-of-service/2025-12-02https://www.dompe.com/us/cookie-policy/2025-12-02https://www.dompe.com/us/supplier-customer-information/2025-12-02https://www.dompe.com/us/accessibility/2025-12-02https://www.dompe.com/us/quality-complaint/2026-05-08https://www.dompe.com/us/medical-information/2026-05-08https://www.dompe.com/us/personal-data-notice-pharmacovigilance/2025-12-02https://www.dompe.com/us/consumer-health-data-privacy-policy/2025-12-02https://www.dompe.com/us/privacy-notice-product-quality-complaints/2025-12-02https://www.dompe.com/us/individual-rights-request-form/2025-12-02https://www.dompe.com/us/404/2025-12-02https://www.dompe.com/us/search/2025-12-02https://www.dompe.com/us/whistleblowing/2025-12-02